Stocks › HRTX

HERON THERAPEUTICS, INC. /DE/

HRTX·Nasdaq·United States United States·USD
$0.25
-0.01 (-4.39%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
HRTX
HERON THERAPEUTICS, INC. /DE/ · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HRTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of HRTX by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Ashley HinsonAshley HinsonHouse · R · IA HRTXHERON THERAPEUTICS, INC. /DE/ · Stock Sale
$1,001 - $15,000
Apr 5, 2021 Mar 31, 2021 Filing ↗

Whale Activity

Position changes in HRTX reported for 2026-09-30 by 180 institutional filers
Increased: 50New: 18Held: 39Decreased: 49Closed: 22No prior filing: 2
  • Increased50
  • New18
  • Held39
  • Decreased49
  • Closed22
  • No prior filing2
FilerSharesValueChange
Rubric Capital Management LP30.0M$9.4Mheld
Clearline Capital LP11.0M$3.5Mdecreased
BlackRock, Inc.9.8M$3.1Mdecreased
TANG CAPITAL MANAGEMENT LLC9.0M$2.8Mincreased
Velan Capital Investment Management LP8.8M$2.7Mheld
VANGUARD CAPITAL MANAGEMENT LLC7.8M$2.5Mincreased
Tejara Capital Ltd6.5M$2.0Mdecreased
GSA CAPITAL PARTNERS LLP5.5M$1.7Mincreased
GEODE CAPITAL MANAGEMENT, LLC4.1M$1.3Mdecreased
STATE STREET CORP3.2M$1.0Mdecreased
UBS Group AG2.1M$661Kdecreased
AQR CAPITAL MANAGEMENT LLC2.0M$623Kincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by HRTX insiders, by quarter · Form 4

No open-market insider buys or sells in the last two years.

Recent Insider Transactions

455 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Hensley Mark EarlChief Operating Officer Tax withholding −8,888 $0.50 $4K Aug 6, 2026 Form 4 ↗
Hensley Mark EarlChief Operating Officer Option exercise +31.3K — — Aug 6, 2026 Form 4 ↗
Hensley Mark EarlChief Operating Officer Option exercise +11.8K — — Jul 31, 2026 Form 4 ↗
Forbes William PEVP, Chief Development Officer Tax withholding −3,326 $0.50 $2K Jul 31, 2026 Form 4 ↗
Forbes William PEVP, Chief Development Officer Option exercise +11.7K — — Jul 31, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Tax withholding −3,326 $0.50 $2K Jul 31, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Option exercise +11.7K — — Jul 31, 2026 Form 4 ↗
Collard Craig AChief Executive Officer · Director Option exercise +34.8K — — Jul 31, 2026 Form 4 ↗
Forbes William PEVP, Chief Development Officer Tax withholding −3,348 $0.50 $2K Jul 30, 2026 Form 4 ↗
Forbes William PEVP, Chief Development Officer Option exercise +11.8K — — Jul 30, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Tax withholding −3,850 $0.50 $2K Jul 30, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Option exercise +13.5K — — Jul 30, 2026 Form 4 ↗
Collard Craig AChief Executive Officer · Director Option exercise +50.0K — — Jul 30, 2026 Form 4 ↗
Collard Craig AChief Executive Officer · Director Option exercise +13.8K — — Jul 19, 2026 Form 4 ↗
Forbes William PEVP, Chief Development Officer Tax withholding −1,101 $0.47 $517 Jul 19, 2026 Form 4 ↗
Forbes William PEVP, Chief Development Officer Option exercise +3,874 — — Jul 19, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Tax withholding −1,101 $0.47 $517 Jul 19, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Option exercise +3,874 — — Jul 19, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Tax withholding −3,555 $0.38 $1K Jun 16, 2026 Form 4 ↗
Duarte IraEVP, Chief Financial Officer Option exercise +12.5K — — Jun 16, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding HRTX · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
5.5M$2.3M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
3.7M$1.6M0.00%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.1M$881K0.00%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.6M$807K0.00%Jul 31, 2026
iShares Russell 2000 Growth ETF
iShares Trust
1.4M$581K0.00%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
912.9K$290K0.00%Aug 31, 2026
Schwab U.S. Small-Cap ETF
SCHWAB STRATEGIC TRUST
861.9K$274K0.00%Aug 31, 2026
iShares Micro-Cap ETF
iShares Trust
537.3K$229K0.02%Jun 30, 2026
iShares Russell 2000 Value ETF
iShares Trust
510.4K$218K0.00%Jun 30, 2026
Schwab Small-Cap Index Fund
SCHWAB CAPITAL TRUST
413.6K$205K0.00%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list HRTX's shares (CUSIP 427746102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Phillip GrossSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    May 13, 2026 · ↗
  • Robert AtchinsonSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    May 13, 2026 · ↗
  • Adage Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    May 13, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming heron therapeutics as client
$0$50K$100K$150K$200K2023 Q1: $50K2023 Q2: $50K2023 Q3: $50K2023 Q4: $50K20232024 Q1: $50K2024 Q2: $50K2024 Q3: $50K2024 Q4: $50K20242025 Q1: $50K2025 Q2: $50K2025 Q3: $50K2025 Q4: $50K20252026 Q1: $50K2026 Q2: $50K2026 Q3: $50K2026
  • FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q3 · HCR, MMM$50K
    Filing ↗
  • FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q2 · HCR, MMM$50K
    Filing ↗
  • FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q1 · HCR, MMM$50K
    Filing ↗
  • FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q4 · HCR, MMM$50K
    Filing ↗
  • FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q3 · HCR, MMM$50K
    Filing ↗

Government Contracts

Federal awards to HERON THERAPEUTICS, INC. /DE/ · USAspending

No federal contract awards found for HERON THERAPEUTICS, INC. /DE/.

U.S. Patents

Recent USPTO applications naming HERON THERAPEUTICS, INC. /DE/

No USPTO patent applications found for HERON THERAPEUTICS, INC. /DE/.

Annual Financials

From HRTX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income-$2.5M-$11.5M-$110.6M-$174.7M-$217.8M
Net income-$20.2M-$13.6M-$110.6M-$182.0M-$220.7M
Diluted EPS-$0.12-$0.09-$0.80-$1.67-$2.24
Operating cash flow-$27.6M-$22.5M-$58.8M-$146.9M-$203.4M
Cash and equivalents$28.6M$25.8M$28.7M$15.4M$90.5M
Total assets$255.9M$233.1M$222.5M$251.0M$305.7M
Total liabilities$241.5M$266.8M$256.5M$237.4M$228.1M
Shareholders' equity$14.3M-$33.7M-$34.0M$13.6M$77.6M

As HERON THERAPEUTICS, INC. /DE/ tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-20Reverse splitJan 13, 2014
  • 1-for-4Reverse splitMay 25, 2007

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 3.03, 7.01, 9.01Material agreement · Modification of rights · Reg FD disclosureNov 9, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 9.01Material agreementSep 29, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 3.03, 9.01Material agreement · Modification of rightsAug 14, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
    EDGAR ↗
  • 8-K · Items 3.01, 9.01Delisting noticeJun 25, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 16, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
    EDGAR ↗

About HERON THERAPEUTICS, INC. /DE/

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
Former namesAP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/